Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmActive, not recruitingPhase 22026-07-15NCT06679985

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Coherus Oncology, Inc.14

44 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Bankstown-Lidcombe HospitalBankstownAustralia6
Beverly Hills Cancer CenterBeverly HillsUnited States26
Cancer & Blood Specialty ClinicLakewoodUnited States1
Chi Mei Medical CenterTainanTaiwan19
China Medical University HospitalTaichungTaiwan1
Christus St. Vincent Regional Medical CenterSanta FeUnited States3
City of HopeDuarteUnited States238
City of Hope at Irvine LennarIrvineUnited States104
Curie OncologySingaporeSingapore4
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterNew YorkUnited States7
Humanity & Health Clinical Trial CentreHong KongHong Kong2
Linear Clinical ResearchNedlandsAustralia6
Linkou Chang Gung Memorial Hospital (CGMHLK)Taoyuan CityTaiwan1
Mayo Clinic - JacksonvilleJacksonvilleUnited States25
Mayo Clinic - ScottsdaleScottsdaleUnited States9
Monash HealthMelbourneAustralia6
Montefiore Medical CenterThe BronxUnited States198
Mountain States Tumor Institute at St. Luke's Regional Medical CenterBoiseUnited States3
National Cancer Centre SingaporeSingaporeSingapore61
National Cheng Kung University HospitalTainanTaiwan1
National Taiwan University HospitalTainanTaiwan1
Prince of Wales HospitalShatinHong Kong14
Princess Margaret HospitalTorontoCanada1
Prisma Health Cancer InstituteGreenvilleUnited States13
Queen Mary HospitalHong KongHong Kong5